Dr. Michael Feigin
About Dr. Michael Feigin
"Dr. Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He earned his Ph.D. under Dr. Craig Malbon at SUNY Stony Brook studying the role of G-protein coupled receptors (GPCRs) and their regulators in the Wnt signaling pathway. Mike then joined the lab of Dr. Senthil Muthuswamy at Cold Spring Harbor Laboratory and probed the roles of polarity proteins (Feigin, et al., Cancer Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches to drug target discovery. When Dr. Muthuswamy moved to the University of Toronto, Mike joined the laboratory of Dr. David Tuveson at CSHL where he participated in the development of an organoid system for the culture of normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development. He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an algorithm for the identification of noncoding mutations driving gene expression in pancreatic cancer (Feigin and Garvin, et al., Nature Genetics, 2017). Mike's lab has two main areas of interest: 1) alternative polyadenylation as a targetable driver of pancreatic cancer, and 2) dysregulation of the pancreatic tumor microenvironment by commonly prescribed anti-anxiety drugs."
Dr. Michael Feigin on the web
Tags